WS
NYMX

Wedbush Securities’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Wedbush Securities’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,100
Closed -$47K – 1014
2020
Q3 		$47K Sell
19,100
-12,500
-40% -$36.4K ﹤0.01% 888
2020
Q2 		$112K Sell
31,600
-2,300
-7% -$7.28K 0.01% 847
2020
Q1 		$79K Sell
33,900
-8,577
-20% -$24.1K 0.01% 794
2019
Q4 		$93K Sell
42,477
-20,223
-32% -$39.9K 0.01% 931
2019
Q3 		$115K Sell
62,700
-58,235
-48% -$102K 0.01% 885
2019
Q2 		$175K Buy
120,935
+7,200
+6% +$12.6K 0.02% 855
2019
Q1 		$224K Sell
113,735
-31,400
-22% -$66.6K 0.02% 724
2018
Q4 		$190K Sell
145,135
-10,850
-7% -$19.9K 0.02% 690
2018
Q3 		$384K Sell
155,985
-63,843
-29% -$189K 0.04% 496
2018
Q2 		$739K Sell
219,828
-28,083
-11% -$108K 0.09% 257
2018
Q1 		$1.05M Sell
247,911
-29,266
-11% -$101K 0.14% 178
2017
Q4 		$915K Buy
277,177
+17,485
+7% +$63.8K 0.11% 221
2017
Q3 		$992K Buy
259,692
+25,000
+11% +$94.8K 0.13% 175
2017
Q2 		$1.03M Buy
234,692
+55,000
+31% +$226K 0.13% 183
2017
Q1 		$652K Buy
179,692
+5,999
+3% +$19.7K 0.09% 275
2016
Q4 		$464K Sell
173,693
-7,252
-4% -$22.5K 0.07% 355
2016
Q3 		$590K Sell
180,945
-30,998
-15% -$101K 0.09% 270
2016
Q2 		$710K Sell
211,943
-650
-0.3% -$1.6K 0.12% 195
2016
Q1 		$519K Sell
212,593
-130
-0.1% -$307 0.09% 249
2015
Q4 		$698K Buy
212,723
+12,575
+6% +$42.2K 0.13% 181
2015
Q3 		$689K Buy
200,148
+3,000
+2% +$6.98K 0.14% 172
2015
Q2 		$262K Sell
197,148
-10,378
-5% -$14.5K 0.05% 473
2015
Q1 		$174K Sell
207,526
-1,000
-0.5% -$472 0.03% 602
2014
Q4 		$83K Buy
208,526
+7,825
+4% +$16.7K 0.01% 659
2014
Q3 		$873K Buy
200,701
+6,855
+4% +$33.6K 0.14% 146
2014
Q2 		$960K Buy
+193,846
New +$998K 0.15% 137

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wedbush Securities's NYMX Position: Q4 2020 in Review

Wedbush Securities sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2020, closing a stake of 19,100 shares — an estimated $47K sold.

Wedbush Securities first reported a position in NYMX in Q2 2014 and held it in 26 quarters. The position peaked at $1.05M in Q1 2018. 58 funds tracked by Wall St. Rank hold NYMX as of Q4 2020.

  • Wedbush Securities reported no remaining Nymox Pharmaceutical Corp position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 19,100 Nymox Pharmaceutical Corp shares in Q4 2020, an estimated $47K.
  • Wedbush Securities first reported a position in Nymox Pharmaceutical Corp in Q2 2014 and held it in 26 quarters.
  • Wedbush Securities's Nymox Pharmaceutical Corp position peaked at $1.05M in Q1 2018.
  • 58 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.